TGK Stock Overview
A healthcare solutions company, provides diagnostic products, reagents, and services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Precipio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.32 |
| 52 Week High | US$17.78 |
| 52 Week Low | US$5.08 |
| Beta | 1.77 |
| 11 Month Change | 0% |
| 3 Month Change | -3.62% |
| 1 Year Change | -49.97% |
| 33 Year Change | -83.88% |
| 5 Year Change | n/a |
| Change since IPO | -95.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| TGK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.02% |
| 1Y | -50.0% | 17.2% | 8.2% |
Return vs Industry: TGK underperformed the German Healthcare industry which returned 12.9% over the past year.
Return vs Market: TGK underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| TGK volatility | |
|---|---|
| TGK Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TGK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TGK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 55 | Ilan Danieli | www.precipiodx.com |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests.
Precipio, Inc. Fundamentals Summary
| TGK fundamental statistics | |
|---|---|
| Market cap | €8.47m |
| Earnings (TTM) | -€8.31m |
| Revenue (TTM) | €12.15m |
0.7x
P/S Ratio-1.0x
P/E RatioIs TGK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TGK income statement (TTM) | |
|---|---|
| Revenue | US$13.26m |
| Cost of Revenue | US$8.66m |
| Gross Profit | US$4.60m |
| Other Expenses | US$13.67m |
| Earnings | -US$9.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.39 |
| Gross Margin | 34.72% |
| Net Profit Margin | -68.39% |
| Debt/Equity Ratio | 3.4% |
How did TGK perform over the long term?
See historical performance and comparison